Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

Schvartsman, Gustavo; Perez, Kristen; Flynn, Jill E.; Myers, Jeffrey N.; Tawbi, Hussein A.

doi:10.1186/s40425-017-0250-5

Cited by 24 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in certain clinical contexts, when treatment options are limited, the unknown risks of postulated AEs must be weighed heavily with the potential of clinical benefit. Recently, T-VEC was shown to be safe and effective in an allogeneic heart-transplant recipient on cyclosporine [ 18 ]. Thus, case reports can provide real-world examples outside of clinical trials or in scenarios cautioned on product labels.…”

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

Miller

Trowbridge

Desai

et al. 2018

j. immunotherapy cancer

View full text Add to dashboard Cite

BackgroundImmune-directed therapies have become front-line therapy for melanoma and are transforming the management of advanced disease. In refractory cases, multi-modal immunoncology (IO) approaches are being utilized, including combining immune checkpoint blockade (ICB) with oncolytic herpes viruses. Talimogene laherparepvec (T-VEC) is the first genetically modified oncolytic viral therapy (OVT) approved for the treatment of recurrent and unresectable melanoma. The use of IO in patients with concomitant malignancies and/or compromised immune systems is limited due to systematic exclusion from clinical trials. For example, a single case report of a solid organ transplant patient successfully treated with T-VEC for metastatic melanoma has been reported. Furthermore, the use of ICB in T-cell malignancies is limited and paradoxical worsening has been described. To our knowledge, this is the first report of dual ICB/T-VEC being administered to a patient with concurrent primary cutaneous anaplastic large cell lymphoma (pcALCL) and melanoma.Case presentationHere we present the case of a patient with concomitant primary cutaneous ALCL and metastatic melanoma, progressing on anti-programmed death (PD)-1 therapy, who developed Kaposi’s varicelliform eruption after receiving the first dose of Talimogene laherparepvec.ConclusionThis case highlights the complexities of care of patients with coexistent cancers, demonstrates rapid progression of primary cutaneous ALCL on nivolumab and introduces a novel adverse effect of Talimogene laherparepvec.

show abstract

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

Miller

Trowbridge

Desai

et al. 2018

j. immunotherapy cancer

View full text Add to dashboard Cite

show abstract

“…This attenuated herpes simplex virus (HSV) is engineered to preferentially replicate in cancer cells and to express the immune-modulatory cytokine GM-CSF which in turn, promotes APCs recruitment to the TME, thereby inducing the anti-tumour immunity [38,103,108]. In the phase III OPTiM clinical trial for treating advanced melanoma, T-Vec treatment showed extended durable response rates and prolonged median overall survival compared with GM-CSF alone, with minimal adverse effects, highlighting the fact that these agents can be safely used in a clinical setting [110][111][112]. Based on these promising results, several OVs are currently being tested in clinical trials: i.e.…”

Section: Oncolytic Virusesmentioning

confidence: 99%

Nanoparticles: Properties and Applications in Cancer Immunotherapy

Iscaro

Howard

Muthana

2019

CPD

View full text Add to dashboard Cite

Background:: Tumours are no longer regarded as isolated masses of aberrantly proliferating epithelial cells. Rather, their properties depend on complex interactions between epithelial cancer cells and the surrounding stromal compartment within the tumour microenvironment. In particular, leukocyte infiltration plays a role in controlling tumour development and is now considered one of the hallmarks of cancer. Thus, in the last few years, immunotherapy has become a promising strategy to fight cancer, as its goal is to reprogram or activate antitumour immunity to kill tumour cells, without damaging the normal cells and provide long-lasting results where other therapies fail. However, the immune-related adverse events due to the low specificity in tumour cell targeting, strongly limit immunotherapy efficacy. In this regard, nanomedicine offers a platform for the delivery of different immunotherapeutic agents specifically to the tumour site, thus increasing efficacy and reducing toxicity. Indeed, playing with different material types, several nanoparticles can be formulated with different shape, charge, size and surface chemical modifications making them the most promising platform for biomedical applications. Aim:: In this review, we will summarize the different types of cancer immunotherapy currently in clinical trials or already approved for cancer treatment. Then, we will focus on the most recent promising strategies to deliver immunotherapies directly to the tumour site using nanoparticles. Conclusions:: Nanomedicine seems to be a promising approach to improve the efficacy of cancer immunotherapy. However, additional investigations are needed to minimize the variables in the production processes in order to make nanoparticles suitable for clinical use.

show abstract

“…239 In summary, this study showed that i.t. injection of T-VEC modifies the TME by attracting T cells and induces a systemic response in distant metastases after subsequent blockade of PD-1 with pembrolizumab (see also: [314][315][316] ). On top of melanoma, intralesional T-VEC is being evaluated in a multicenter Phase Ib study against recurrent or metastatic HNC in combination with pembrolizumab (NCT02626000/MASTERKEY-232).…”

Section: Completed and Advanced Clinical Studiesmentioning

confidence: 99%

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

et al. 2018

View full text Add to dashboard Cite

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

show abstract

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

Cited by 24 publications

References 22 publications

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

Nanoparticles: Properties and Applications in Cancer Immunotherapy

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Contact Info

Product

Resources

About